Elevated endogenous erythropoietin concentrations are associated with increased risk of brain damage in extremely preterm neonates

Steven J Korzeniewski, Elizabeth Allred, J Wells Logan, Raina N Fichorova, Stephen Engelke, Karl C K Kuban, T Michael O'Shea, Nigel Paneth, Mari Holm, Olaf Dammann, Alan Leviton, ELGAN study investigators, Kathleen Lee, Anne McGovern, Jill Gambardella, Susan Ursprung, Ruth Blomquist, Kristen Ecklund, Haim Bassan, Samantha Butler, Adré Duplessis, Cecil Hahn, Catherine Limperopoulos, Omar Khwaja, Janet S Soul, Bhavesh Shah, Karen Christianson, Frederick Hampf, Herbert Gilmore, Susan McQuiston, Camilia R Martin, Colleen Hallisey, Caitlin Hurley, Miren Creixell, Jane Share, Linda J Van Marter, Sara Durfee, Robert M Insoft, Jennifer G Wilson, Maureen Pimental, Sjirk J Westra, Kalpathy Krishnamoorthy, Cynthia Cole, John M Fiascone, Janet Madden, Ellen Nylen, Anne Furey, Roy McCauley, Paige T Church, Cecelia Keller, Karen J Miller, Francis Bednarek, Mary Naples, Beth Powers, Jacqueline Wellman, Robin Adair, Richard Bream, Alice Miller, Albert Scheiner, Christy Stine, Richard Ehrenkranz, Joanne Williams, Elaine Romano, Cindy Miller, T Michael O'Shea, Debbie Gordon, Teresa Harold, Barbara Specter, Deborah Allred, Robert Dillard, Don Goldstein, Deborah Hiatt, Gail Hounshell, Ellen Waldrep, Lisa Washburn, Cherrie D Welch, Stephen C Engelke, Sherry Moseley, Linda Pare, Donna Smart, Joan Wilson, Ira Adler, Sharon Buckwald, Rebecca Helms, Kathyrn Kerkering, Scott S MacGilvray, Peter Resnik, Carl Bose, Gennie Bose, Lynn A Fordham, Lisa Bostic, Diane Marshall, Kristi Milowic, Janice Wereszczak, Mariel Poortenga, Dinah Sutton, Bradford W Betz, Steven L Bezinque, Joseph Junewick, Wendy Burdo-Hartman, Lynn Fagerman, Kim Lohr, Steve Pastyrnak, Carolyn Solomon, Ellen Cavenagh, Victoria J Caine, Nicholas Olomu, Joan Price, Nigel Paneth, Padmani Karna, Madeleine Lenski, Michael D Schreiber, Grace Yoon, Kate Feinstein, Leslie Caldarelli, Sunila E O'Connor, Michael Msall, Susan Plesha-Troyke, Daniel Batton, Beth Kring, Karen Brooklier, Melisa J Oca, Katherine M Solomon, Joanna J Seibert, Robert Lorenzo, Steven J Korzeniewski, Elizabeth Allred, J Wells Logan, Raina N Fichorova, Stephen Engelke, Karl C K Kuban, T Michael O'Shea, Nigel Paneth, Mari Holm, Olaf Dammann, Alan Leviton, ELGAN study investigators, Kathleen Lee, Anne McGovern, Jill Gambardella, Susan Ursprung, Ruth Blomquist, Kristen Ecklund, Haim Bassan, Samantha Butler, Adré Duplessis, Cecil Hahn, Catherine Limperopoulos, Omar Khwaja, Janet S Soul, Bhavesh Shah, Karen Christianson, Frederick Hampf, Herbert Gilmore, Susan McQuiston, Camilia R Martin, Colleen Hallisey, Caitlin Hurley, Miren Creixell, Jane Share, Linda J Van Marter, Sara Durfee, Robert M Insoft, Jennifer G Wilson, Maureen Pimental, Sjirk J Westra, Kalpathy Krishnamoorthy, Cynthia Cole, John M Fiascone, Janet Madden, Ellen Nylen, Anne Furey, Roy McCauley, Paige T Church, Cecelia Keller, Karen J Miller, Francis Bednarek, Mary Naples, Beth Powers, Jacqueline Wellman, Robin Adair, Richard Bream, Alice Miller, Albert Scheiner, Christy Stine, Richard Ehrenkranz, Joanne Williams, Elaine Romano, Cindy Miller, T Michael O'Shea, Debbie Gordon, Teresa Harold, Barbara Specter, Deborah Allred, Robert Dillard, Don Goldstein, Deborah Hiatt, Gail Hounshell, Ellen Waldrep, Lisa Washburn, Cherrie D Welch, Stephen C Engelke, Sherry Moseley, Linda Pare, Donna Smart, Joan Wilson, Ira Adler, Sharon Buckwald, Rebecca Helms, Kathyrn Kerkering, Scott S MacGilvray, Peter Resnik, Carl Bose, Gennie Bose, Lynn A Fordham, Lisa Bostic, Diane Marshall, Kristi Milowic, Janice Wereszczak, Mariel Poortenga, Dinah Sutton, Bradford W Betz, Steven L Bezinque, Joseph Junewick, Wendy Burdo-Hartman, Lynn Fagerman, Kim Lohr, Steve Pastyrnak, Carolyn Solomon, Ellen Cavenagh, Victoria J Caine, Nicholas Olomu, Joan Price, Nigel Paneth, Padmani Karna, Madeleine Lenski, Michael D Schreiber, Grace Yoon, Kate Feinstein, Leslie Caldarelli, Sunila E O'Connor, Michael Msall, Susan Plesha-Troyke, Daniel Batton, Beth Kring, Karen Brooklier, Melisa J Oca, Katherine M Solomon, Joanna J Seibert, Robert Lorenzo

Abstract

Background: We sought to determine, in very preterm infants, whether elevated perinatal erythropoietin (EPO) concentrations are associated with increased risks of indicators of brain damage, and whether this risk differs by the co-occurrence or absence of intermittent or sustained systemic inflammation (ISSI).

Methods: Protein concentrations were measured in blood collected from 786 infants born before the 28th week of gestation. EPO was measured on postnatal day 14, and 25 inflammation-related proteins were measured weekly during the first 2 postnatal weeks. We defined ISSI as a concentration in the top quartile of each of 25 inflammation-related proteins on two separate days a week apart. Hypererythropoietinemia (hyperEPO) was defined as the highest quartile for gestational age on postnatal day 14. Using logistic regression and multinomial logistic regression models, we compared risks of brain damage among neonates with hyperEPO only, ISSI only, and hyperEPO+ISSI, to those who had neither hyperEPO nor ISSI, adjusting for gestational age.

Results: Newborns with hyperEPO, regardless of ISSI, were more than twice as likely as those without to have very low (< 55) Mental (OR 2.3; 95% CI 1.5-3.5) and/or Psychomotor (OR 2.4; 95% CI 1.6-3.7) Development Indices (MDI, PDI), and microcephaly at age two years (OR 2.4; 95%CI 1.5-3.8). Newborns with both hyperEPO and ISSI had significantly increased risks of ventriculomegaly, hemiparetic cerebral palsy, microcephaly, and MDI and PDI < 55 (ORs ranged from 2.2-6.3), but not hypoechoic lesions or other forms of cerebral palsy, relative to newborns with neither hyperEPO nor ISSI.

Conclusion: hyperEPO, regardless of ISSI, is associated with elevated risks of very low MDI and PDI, and microcephaly, but not with any form of cerebral palsy. Children with both hyperEPO and ISSI are at higher risk than others of very low MDI and PDI, ventriculomegaly, hemiparetic cerebral palsy, and microcephaly.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1. Odds ratios (and 95% confidence…
Fig 1. Odds ratios (and 95% confidence intervals) for ventriculomegaly (A.) and hypoechoic lesion (B.) calculated with logistic regression models.
The three risk groups: ISSI only: (an inflammation-related protein concentration in the highest quartile on two days); hyperEPO only (an EPO concentration in the highest quartile on day 14); and ISSI+hyperEPO are each compared to the referent group that consists of newborns who had neither ISSI nor hyperEPO. All models are adjusted for gestational age.
Fig 2. Odds ratios (and 95% confidence…
Fig 2. Odds ratios (and 95% confidence intervals) of quadriparesis (A.), diparesis (B.) and hemiparesis (C.) calculated with multinomial logistic regression models with risk groups and adjustment for gestational age as described in Fig. 1.
Missing values indicate an inability to estimate odds due to complete separation of outcomes among exposed and unexposed in light of the small sample size.
Fig 3. Odds ratios (and 95% confidence…
Fig 3. Odds ratios (and 95% confidence intervals) of Very Low Mental Development Index (A.) and Very Low Psychomotor Development Index (B.) calculated with multinomial logistic regression models as described in Fig. 2.
Note: Only children with a GMFCS

Fig 4. Odds ratios (and 95% confidence…

Fig 4. Odds ratios (and 95% confidence intervals) of 24 month head circumference Z-score <…

Fig 4. Odds ratios (and 95% confidence intervals) of 24 month head circumference Z-score < -2 calculated with logistic regression models as described in Fig. 1.
Note: Children with a birth head circumference Z-score

Fig 5. Summary of Associations.

We identify…

Fig 5. Summary of Associations.

We identify three patterns of increased risk of indicators of…

Fig 5. Summary of Associations.
We identify three patterns of increased risk of indicators of brain damage associated with hyperEPO and ISSI. hyperEPO only is identified with yellow, ISSI only is identified with orange, and the combination of ISSI+hyperEPO is identified with red. Reduced risk of an echolucent lesion associated with hyperEPO only is identified with green. Boxes with 2 or 3 separate colors indicate that 2 or 3 patterns were identified. Note: Cells in this table identify patterns of results of unique multivariable regression models fitted to answer whether or not children in each of three mutually exclusive study groups (hyperEPO only, ISSI only, or hyperEPO+ISSI) were at higher or lower risk of the brain damage indicator identified at the top of each column, relative to those in a referent group who did not have hyperEPO or ISSI, adjusting for gestational age category.
Similar articles
Cited by
References
    1. Nagao M, Masuda S, Abe S, Ueda M, Sasaki R (1992) Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor. Biochem Biophys Res Commun 188: 888–897. - PubMed
    1. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, et al. (1994) A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 269: 19488–19493. - PubMed
    1. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R (1997) Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76: 105–116. - PubMed
    1. Bierer R, Peceny MC, Hartenberger CH, Ohls RK (2006) Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 118: e635–640. - PubMed
    1. Neubauer A-P, Voss W, Wachtendorf M, Jungmann T (2010) Erythropoietin Improves Neurodevelopmental Outcome of Extremely Preterm Infants. Annals of Neurology 67: 657–666. 10.1002/ana.21977 - DOI - PubMed
Show all 50 references
Publication types
MeSH terms
[x]
Cite
Copy Download .nbib
Format: AMA APA MLA NLM
Fig 4. Odds ratios (and 95% confidence…
Fig 4. Odds ratios (and 95% confidence intervals) of 24 month head circumference Z-score < -2 calculated with logistic regression models as described in Fig. 1.
Note: Children with a birth head circumference Z-score

Fig 5. Summary of Associations.

We identify…

Fig 5. Summary of Associations.

We identify three patterns of increased risk of indicators of…

Fig 5. Summary of Associations.
We identify three patterns of increased risk of indicators of brain damage associated with hyperEPO and ISSI. hyperEPO only is identified with yellow, ISSI only is identified with orange, and the combination of ISSI+hyperEPO is identified with red. Reduced risk of an echolucent lesion associated with hyperEPO only is identified with green. Boxes with 2 or 3 separate colors indicate that 2 or 3 patterns were identified. Note: Cells in this table identify patterns of results of unique multivariable regression models fitted to answer whether or not children in each of three mutually exclusive study groups (hyperEPO only, ISSI only, or hyperEPO+ISSI) were at higher or lower risk of the brain damage indicator identified at the top of each column, relative to those in a referent group who did not have hyperEPO or ISSI, adjusting for gestational age category.
Fig 5. Summary of Associations.
Fig 5. Summary of Associations.
We identify three patterns of increased risk of indicators of brain damage associated with hyperEPO and ISSI. hyperEPO only is identified with yellow, ISSI only is identified with orange, and the combination of ISSI+hyperEPO is identified with red. Reduced risk of an echolucent lesion associated with hyperEPO only is identified with green. Boxes with 2 or 3 separate colors indicate that 2 or 3 patterns were identified. Note: Cells in this table identify patterns of results of unique multivariable regression models fitted to answer whether or not children in each of three mutually exclusive study groups (hyperEPO only, ISSI only, or hyperEPO+ISSI) were at higher or lower risk of the brain damage indicator identified at the top of each column, relative to those in a referent group who did not have hyperEPO or ISSI, adjusting for gestational age category.

References

    1. Nagao M, Masuda S, Abe S, Ueda M, Sasaki R (1992) Production and ligand-binding characteristics of the soluble form of murine erythropoietin receptor. Biochem Biophys Res Commun 188: 888–897.
    1. Masuda S, Okano M, Yamagishi K, Nagao M, Ueda M, et al. (1994) A novel site of erythropoietin production. Oxygen-dependent production in cultured rat astrocytes. J Biol Chem 269: 19488–19493.
    1. Morishita E, Masuda S, Nagao M, Yasuda Y, Sasaki R (1997) Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76: 105–116.
    1. Bierer R, Peceny MC, Hartenberger CH, Ohls RK (2006) Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 118: e635–640.
    1. Neubauer A-P, Voss W, Wachtendorf M, Jungmann T (2010) Erythropoietin Improves Neurodevelopmental Outcome of Extremely Preterm Infants. Annals of Neurology 67: 657–666. 10.1002/ana.21977
    1. Ohls RK, Kamath-Rayne BD, Christensen RD, Wiedmeier SE, Rosenberg A, et al. (2014) Cognitive Outcomes of Preterm Infants Randomized to Darbepoetin, Erythropoietin, or Placebo. Pediatrics 133: 1023–1030. 10.1542/peds.2013-4307
    1. Zhu C, Kang W, Xu F, Cheng X, Zhang Z, et al. (2009) Erythropoietin Improved Neurologic Outcomes in Newborns With Hypoxic-Ischemic Encephalopathy. Pediatrics 124: E218–E226. 10.1542/peds.2008-3553
    1. Brown MS, Eichorst D, LaLa-Black B, Gonzalez R (2009) Higher Cumulative Doses of Erythropoietin and Developmental Outcomes in Preterm Infants. Pediatrics 124: E681–E687. 10.1542/peds.2008-2701
    1. Leviton A, Kuban KCK, Allred EN, Fichorova RN, O'Shea TM, et al. (2011) Early postnatal blood concentrations of inflammation-related proteins and microcephaly two years later in infants born before the 28th post-menstrual week. Early Human Development 87: 325–330. 10.1016/j.earlhumdev.2011.01.043
    1. Leviton A, Kuban K, O'Shea TM, Paneth N, Fichorova R, et al. (2011) The Relationship between Early Concentrations of 25 Blood Proteins and Cerebral White Matter Injury in Preterm Newborns: The ELGAN Study. The Journal of Pediatrics 158: 897–903.e895. 10.1016/j.jpeds.2010.11.059
    1. O'Shea TM, Allred EN, Kuban KCK, Dammann O, Paneth N, et al. (2012) Elevated Concentrations of Inflammation-Related Proteins in Postnatal Blood Predict Severe Developmental Delay at 2 Years of Age in Extremely Preterm Infants. Journal of Pediatrics 160: 395–401. 10.1016/j.jpeds.2011.08.069
    1. O'Shea TM, Shah B, Allred EN, Fichorova RN, Kuban KC, et al. (2013) Inflammation-initiating illnesses, inflammation-related proteins, and cognitive impairment in extremely preterm infants. Brain, Behavior, and Immunity 29: 104–112. 10.1016/j.bbi.2012.12.012
    1. Leviton A, Fichorova RN, O'Shea TM, Kuban K, Paneth N, et al. (2013) Two-hit model of brain damage in the very preterm newborn: small for gestational age and postnatal systemic inflammation. Pediatric Research 73: 362–370. 10.1038/pr.2012.188
    1. Lee SH, Li C, Lim SW, Ahn KO, Choi BS, et al. (2005) Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol 25: 64–76.
    1. Contaldo C, Lindenblatt N, Elsherbiny A, Hogger DC, Borozadi MK, et al. (2011) Erythropoietin requires endothelial nitric oxide synthase to counteract TNF-[alpha]-induced microcirculatory dysfunction in murine striated muscle. Shock 35: 315–321. 10.1097/SHK.0b013e3181fd0700
    1. Wells Logan J, Allred EN, Fichorova RN, Engelke S, Dammann O, et al. (2014) Endogenous erythropoietin varies significantly with inflammation-related proteins in extremely premature newborns. Cytokine 69: 22–28. 10.1016/j.cyto.2014.04.009
    1. O'Shea TM, Allred EN, Dammann O, Hirtz D, Kuban KC, et al. (2009) The ELGAN study of the brain and related disorders in extremely low gestational age newborns. Early Hum Dev 85: 719–725. 10.1016/j.earlhumdev.2009.08.060
    1. Yudkin PL, Aboualfa M, Eyre JA, Redman CW, Wilkinson AR (1987) New birthweight and head circumference centiles for gestational ages 24 to 42 weeks. Early Hum Dev 15: 45–52.
    1. Leviton A, Paneth N, Reuss ML, Susser M, Allred EN, et al. (1999) Maternal infection, fetal inflammatory response, and brain damage in very low birthweight infants. Pediatric Research 46: 566–575.
    1. Hecht JL, Fichorova RN, Tang VF, Allred EN, McElrath TF, et al. (2011) Relationship between neonatal blood protein profiles and placenta histologic characteristics in ELGANs. Pediatr Research 69: 68–73. 10.1203/PDR.0b013e3181fed334
    1. Leviton A, Fichorova R, Yamamoto Y, Allred EN, Dammann O, et al. (2011) Inflammation-related proteins in the blood of extremely low gestational age newborns. The contribution of inflammation to the appearance of developmental regulation. Cytokine 53: 66–73. 10.1016/j.cyto.2010.09.003
    1. Fichorova RN, Trifonova RT, Gilbert RO, Costello CE, Hayes GR, et al. (2006) Trichomonas vaginalis lipophosphoglycan triggers a selective upregulation of cytokines by human female reproductive tract epithelial cells. Infect Immun 74: 5773–5779.
    1. Fichorova RN, Richardson-Harman N, Alfano M, Belec L, Carbonneil C, et al. (2008) Biological and technical variables affecting immunoassay recovery of cytokines from human serum and simulated vaginal fluid: a multicenter study. Anal Chem 80: 4741–4751. 10.1021/ac702628q
    1. Fichorova RN, Onderdonk AB, Yamamoto H, M.L. D, Dubois AM, et al. (2011) Microbe-specific modulation of inflammatory response in extremely low gestational age newborns. mBio 2: e00280–00210. 10.1128/mBio.00280-11
    1. McElrath TF, Fichorova RN, Allred EN, Hecht JL, Ismail MA, et al. (2011) Blood protein profiles of infants born before 28 weeks differ by pregnancy complication. Am J Obstet Gynecol 204: 418.e411–418.e412. 10.1016/j.ajog.2010.12.010
    1. Fichorova RN, Onderdonk AB, Yamamoto H, Delaney ML, DuBois AM, et al. (2011) Maternal microbe-specific modulation of inflammatory response in extremely low-gestational-age newborns. MBio 2: e00280–00210. 10.1128/mBio.00280-11
    1. Kuban K, Adler I, Allred EN, Batton D, Bezinque S, et al. (2007) Observer variability assessing US scans of the preterm brain: the ELGAN study. Pediatr Radiol 37: 1201–1208
    1. Bayley N (1993) Bayley Scales of Infant Development-II.: Psychological Corporation, San Antonio, TX.
    1. Kuban KC, O'Shea M, Allred E, Leviton A, Gilmore H, et al. (2005) Video and CD-ROM as a training tool for performing neurologic examinations of 1-year-old children in a multicenter epidemiologic study. J Child Neurol 20: 829–831.
    1. CDC (2007) CDC Growth Charts: United States .
    1. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, et al. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15: 103–113. 10.1016/j.ccr.2009.01.001
    1. O'Shea TM, Allred EN, Kuban KC, Dammann O, Paneth N, et al. (2012) Elevated concentrations of inflammation-related proteins in postnatal blood predict severe developmental delay at 2 years of age in extremely preterm infants. J Pediatr 160: 395–401 e394. 10.1016/j.jpeds.2011.08.069
    1. Kuban KC, O'Shea TM, Allred EN, Paneth N, Hirtz D, et al. (2014) Systemic Inflammation and Cerebral Palsy Risk in Extremely Preterm Infants. J Child Neurol [Epub ahead of print, March 18].
    1. Wu YW, Bauer LA, Ballard RA, Ferriero DM, Glidden DV, et al. (2012) Erythropoietin for Neuroprotection in Neonatal Encephalopathy: Safety and Pharmacokinetics. Pediatrics 130: 683–691. 10.1542/peds.2012-0498
    1. Brines M, Cerami A (2008) Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response. Journal of Internal Medicine 264: 405–432. 10.1111/j.1365-2796.2008.02024.x
    1. Iwai M, Liu JL, Yin W, Cao GD, Signore AP, et al. (2007) Erythropoietin enhances angiogenesis and neuronal replacement in cerebral cortex after neonatal hypoxia-ischemia. Stroke 38: 557–558.
    1. Kertesz N, Wu J, Chen THP, Sucov HM, Wu H (2004) The role of erythropoietin in regulating angiogenesis. Developmental Biology 276: 101–110.
    1. Ashley RA, Dubuque SH, Dvorak B, Woodward SS, Williams SK, et al. (2002) Erythropoietin stimulates vasculogenesis in neonatal rat mesenteric microvascular endothelial cells. Pediatric Research 51: 472–478.
    1. Marti HH, Bernaudin M, Petit E, Bauer C (2000) Neuroprotection and angiogenesis: Dual role of erythropoietin in brain ischemia. News in Physiological Sciences 15: 225–229.
    1. Carlini RG, Reyes AA, Rothstein M (1995) RECOMBINANT-HUMAN-ERYTHROPOIETIN STIMULATES ANGIOGENESIS IN-VITRO. Kidney International 47: 740–745.
    1. Liu W, Shen Y, Plane JM, Pleasure DE, Deng W (2011) Neuroprotective potential of erythropoietin and its derivative carbamylated erythropoietin in periventricular leukomalacia. Experimental Neurology 230: 227–239. 10.1016/j.expneurol.2011.04.021
    1. Iwai M, Stetler RA, Xing J, Hu XM, Gao YQ, et al. (2010) Enhanced Oligodendrogenesis and Recovery of Neurological Function by Erythropoietin After Neonatal Hypoxic/Ischemic Brain Injury. Stroke 41: 1032–1037. 10.1161/STROKEAHA.109.570325
    1. Byts N, Siren A-L (2009) Erythropoietin: a multimodal neuroprotective agent. Experimental & Translational Stroke Medicine 1: 1–4.
    1. Sasaki R (2003) Pleiotropic functions of erythropoietin. Intern Med 42: 142–149.
    1. Schultz C, Zimmer J, Haertel C, Rupp J, Temming P, et al. (2008) Attenuation of monocyte proinflammatory cytokine responses to Neisseria meningitidis in children by erythropoietin. Clinical and Experimental Immunology 154: 187–191. 10.1111/j.1365-2249.2008.03760.x
    1. Kumral A, Baskin H, Yesilirmak DC, Ergur BU, Aykan S, et al. (2007) Erythropoietin attenuates lipopolysaccharide-induced white matter injury in the neonatal rat brain. Neonatology 92: 269–278.
    1. Chong ZZ, Li FQ, Maiese K (2005) Erythropoictin requires NF-kappa B and its nuclear translocation to prevent early and late apoptotic neuronal injury during beta-amyloid toxicity. Current Neurovascular Research 2: 387–399.
    1. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, et al. (2003) Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. Journal of Experimental Medicine 198: 971–975.
    1. Agnello D, Bigini P, Villa P, Mennini T, Cerami A, et al. (2002) Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis. Brain Research 952: 128–134.
    1. Arnold CC, Kramer MS, Hobbs CA, McLean FH, Usher RH (1991) Very low birth weight: a problematic cohort for epidemiologic studies of very small or immature neonates. Am J Epidemiol 134: 604–613.

Source: PubMed

3
S'abonner